OmniAb

Palo Alto, United States Founded: 2012 • Age: 14 yrs Acquired By Ligand Pharmaceuticals
Transgenic animal platforms are developed for human therapeutic antibody production.

About OmniAb

OmniAb is a company based in Palo Alto (United States) founded in 2012 was acquired by Ligand Pharmaceuticals in December 2015.. The company has 114 employees as of December 31, 2024. OmniAb offers products and services including OmniRat, OmniMouse, OmniChicken, and GEM xPloration. OmniAb operates in a competitive market with competitors including Adimab, Aphios, CDI Labs, QuaDRAD and AbCheck, among others.

  • Headquarter Palo Alto, United States
  • Employees 114 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Omniab, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
    $26.39 M
    -22.75
    as on Dec 31, 2024
  • Net Profit
    $-62.03 M
    -22.55
    as on Dec 31, 2024
  • EBITDA
    $-53.28 M
    -7.14
    as on Dec 31, 2024
  • Latest Funding Round
    $30 M (USD), Post-IPO

    Aug 25, 2025

  • Investors
  • Employee Count
    114

    as on Dec 31, 2024

  • Acquired by
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of OmniAb

OmniAb is a publicly listed company on the NASDAQ with ticker symbol OABI in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: OABI . Sector: Commercial services · USA

Products & Services of OmniAb

OmniAb offers a comprehensive portfolio of products and services, including OmniRat, OmniMouse, OmniChicken, and GEM xPloration. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Enables generation of human antibodies for therapeutic research.

Facilitates antibody production and diversity in drug development.

Supports discovery of single-domain antibodies for various applications.

Offers advanced tools for antibody repertoire exploration.

People of OmniAb
Headcount 50-200
Employee Profiles 7
Employee Profiles
People
Eric Vajda
Vice President Pre-clinical Research and Development
People
Christel Iffland
Sr Vice President, Antibody Technologies
People
Marie-Cecile Van De Lavoir
Senior VP Technical Operations & Animal Genetics
People
Todd Pettingill, CFA
Vice President, Business Development and Strategy

Unlock access to complete

Funding Insights of OmniAb

  • Total Funding
  • Total Rounds 1
  • Last Round Post-IPO — $30.0M
  • First Round

    (25 Aug 2025)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2025 Amount Post-IPO - OmniAb Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in OmniAb

OmniAb has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Pharmaceutical drugs are manufactured and developed in the United States.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by OmniAb

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - OmniAb

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Omniab Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of OmniAb

OmniAb operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adimab, Aphios, CDI Labs, QuaDRAD and AbCheck, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Antibodies are discovered and optimized for autoimmune and infectious diseases.
domain founded_year HQ Location
Therapeutics for cancer and infectious diseases are developed.
domain founded_year HQ Location
Autoantibody detection and profiling products and services are provided.
domain founded_year HQ Location
Antibody drug discovery platform
domain founded_year HQ Location
Developer of human therapeutic antibodies
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about OmniAb

When was OmniAb founded?

OmniAb was founded in 2012 and raised its 1st funding round 13 years after it was founded.

Where is OmniAb located?

OmniAb is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.

How many employees does OmniAb have?

As of Dec 31, 2024, the latest employee count at OmniAb is 114.

What is the annual revenue of OmniAb?

Annual revenue of OmniAb is $26.39M as on Dec 31, 2024.

What does OmniAb do?

OmniAb was founded in 2012 and is based in Palo Alto, United States, within the biotechnology sector. Three transgenic platformsOmniRat, OmniMouse, and OmniFlicare employed to generate mono- and bispecific human antibodies. These systems, utilizing patented technology, enable diverse antibody repertoires with high affinity and stability. Licensing agreements are extended to pharmaceutical and biotech firms worldwide, covering various targets, indications, and territories through flexible terms.

Who are the top competitors of OmniAb?

OmniAb's top competitors include Adimab, Aphios and CDI Labs.

What products or services does OmniAb offer?

OmniAb offers OmniRat, OmniMouse, OmniChicken, and GEM xPloration.

Is OmniAb publicly traded?

Yes, OmniAb is publicly traded on NASDAQ under the ticker symbol OABI.

Who are OmniAb's investors?

OmniAb has 1 investor. Key investors include Ligand Pharmaceuticals.

What is OmniAb's ticker symbol?

The ticker symbol of OmniAb is OABI on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available